CSIMarket
 
Sigilon Therapeutics Inc   (SGTX)
Other Ticker:  
 
 
Price: $22.4700 $-0.59 -2.559%
Day's High: $23.1 Week Perf: 3.98 %
Day's Low: $ 22.09 30 Day Perf: 4.27 %
Volume (M): 84 52 Wk High: $ 28.00
Volume (M$): $ 1,878 52 Wk Avg: $8.02
Open: $22.90 52 Wk Low: $0.45



 Market Capitalization (Millions $) 56
 Shares Outstanding (Millions) 3
 Employees -
 Revenues (TTM) (Millions $) 18
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 1

Sigilon Therapeutics Inc
Sigilon Therapeutics Inc is a biotechnology company that specializes in developing and commercializing cell therapies for chronic and debilitating diseases. The company focuses on creating Shielded Living Therapeutics', which are therapeutic cells engineered to produce and deliver proteins to treat a wide range of diseases.

Sigilon's proprietary technology enables the encapsulation of therapeutic cells within a biocompatible and immune-privileged matrix, known as Afibromer'. This matrix protects the therapeutic cells from the immune system, allowing for long-term and sustained protein production. By delivering protein-based therapies, Sigilon aims to address the underlying cause of diseases rather than solely managing symptoms.

The company's pipeline includes treatments for hematologic disorders, enzyme deficiencies, endocrine disorders, and more. Sigilon's approach has the potential to revolutionize the treatment options for patients suffering from chronic diseases, offering long-term solutions with reduced side effects and improved efficacy.

Sigilon Therapeutics Inc was founded in 2013 and is headquartered in Cambridge, Massachusetts. The company continues to advance its research and development activities to bring transformative therapies to patients in need.


   Company Address: 100 Binney Street, Suite 600 Cambridge 2142 MA
   Company Phone Number: 336-7540   Stock Exchange / Ticker: NASDAQ SGTX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Sigilon Therapeutics Inc

Despite Mammoth Revenue Surge, 'Sigilon Therapeutics Inc.' Struggles to Achieve Profitability in Q2 2023- An Unexpected Paradox.



The stock market is a dynamic and ever-changing landscape, where investors are constantly seeking promising opportunities. Today, we bring you exciting news about Sigilon Therapeutics Inc (SGTX), a company that has showcased remarkable growth and potential in the financial time-frame ending June 30, 2023. Despite a slight increase in the shortfall per share, SGTX's robust revenue rise of 104.648% has captured the attention of investors, demonstrating their strong position in the market.
Positive Revenue Growth:
SGTX has reported a substantial increase in revenue, amounting to $5.90 million, reflecting a year-on-year growth of 104.648%. This achievement is particularly impressive given the challenging economic climate during this period. Furthermore, compared to the previous reporting season, the revenue improved by 21.449% from $4.86 million.

Sigilon Therapeutics Inc

Sigilon Therapeutics Inc Reports Significant Net Losses of $37 Million in Q1 2023, Indicating Struggling Profits and Lagging Performance Compared to Peers

Sigilon Therapeutics Inc is a pharmaceutical company that has recorded a cumulative net loss of $-37 million during the 12 months ending in the first quarter of 2023. As a result, the company's Return on Equity (ROE) is -87.94%, which is negative. This indicates that the company is not generating profits for its shareholders.
It is worth noting that within the Major Pharmaceutical Preparations industry, Sigilon Therapeutics Inc is behind 109 other companies that have higher returns on equity. This means that the company is not performing as well as its peers in the industry. However, the overall ranking of its return on equity has improved in the first quarter of 2023 compared to the fourth quarter of 2022. The overall ranking has advanced to 1986, up from 3857 in the previous quarter.






 

Sigilon Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com